Please enable JavaScript to continue using this application.

Compare $INBX vs $TSHA | Chartloom

Compare

$INBX vs $TSHA

Inhibrx Biosciences Inc · Taysha Gene Therapies Inc

INBX

Inhibrx Biosciences Inc

TSHA

Taysha Gene Therapies Inc

Compare $INBX vs $TSHA

Comparing Inhibrx Biosciences Inc and Taysha Gene Therapies Inc

INBXInhibrx Biosciences Inc

TSHATaysha Gene Therapies Inc

INBXInhibrx Biosciences Inc

Market cap

$1.39B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-100.0%

YTD performance

26.6%

52W performance

182.7%

FCF yield

-9.5%

TSHATaysha Gene Therapies Inc

Market cap

$1.44B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

664.56x

Rev growth (TTM)

-32.3%

YTD performance

-14.5%

52W performance

-11.3%

FCF yield

-9.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

INBX

TSHA

Detailed metrics comparison

INBX

Inhibrx Biosciences Inc

TSHA

Taysha Gene Therapies Inc

Market Cap

INBX$1.39B

TSHA$1.44B

Enterprise Value

INBX$1.44B

TSHA$1.03B

Price

INBX$95.01

TSHA$4.49

P/E Ratio

INBXN/A

TSHAN/A

P/S Ratio

INBX1,019.62x

TSHA261.77x

EV/Sales

INBX1,050.29x

TSHA187.75x

EV/EBITDA

INBX0.85x

TSHA0.00x

P/B Ratio

INBX178.59x

TSHA3.90x

P/FCF Ratio

INBXN/A

TSHAN/A

EV/FCF

INBX-10.89x

TSHA-7.77x

PEG Ratio

INBXN/A

TSHAN/A

Forward P/E (NTM)

INBXN/A

TSHAN/A

Forward P/S (NTM)

INBXN/A

TSHA664.56x

Revenue (TTM)

INBX$0

TSHA$5M

Revenue Growth (YoY)

INBX-100.0%

TSHA-32.3%

Forward Rev Growth

INBX282.8%

TSHA1272.3%

Gross Margin (TTM)

INBX0.0%

TSHA0.0%

Operating Margin (TTM)

INBX0.0%

TSHA0.0%

EBITDA Margin (TTM)

INBX0.0%

TSHA-2833.6%

Net Margin (TTM)

INBX0.0%

TSHA-2728.0%

FCF Margin (TTM)

INBXN/A

TSHA-2417.0%

Net Income (TTM)

INBX$-138M

TSHA$-150M

FCF (TTM)

INBX$-132M

TSHA$-133M

EPS (TTM)

INBX-$8.82

TSHA-$0.41

ROE (TTM)

INBX-26956.0%

TSHA-5619.0%

ROA (TTM)

INBX-8348.0%

TSHA-4184.0%

ROIC (TTM)

INBX-9241.0%

TSHA-4729.0%

Cash

INBX$133M

TSHA$455M

Debt

INBX$176M

TSHA$49M

Net Cash/Debt

INBX$-43M

TSHA$406M

Current Ratio (TTM)

INBX5.07x

TSHA17.76x

Quick Ratio (TTM)

INBX4.76x

TSHA17.57x

Debt/Equity (TTM)

INBX12.58x

TSHA0.13x

Debt/Assets (TTM)

INBX0.0%

TSHA0.0%

Interest Coverage (TTM)

INBXN/A

TSHAN/A

Net Debt/EBITDA (TTM)

INBX0.00x

TSHA0.00x

Beta

INBX3.17

TSHA1.37

52W Performance

INBX182.7%

TSHA-11.3%

YTD Performance

INBX26.6%

TSHA-14.5%

% from 52W High

INBX-38.8%

TSHA-38.5%

% from 52W Low

INBX237.4%

TSHA21.6%

Asset Turnover (TTM)

INBX0.01x

TSHA0.04x

FCF Yield (TTM)

INBX-9.5%

TSHA-9.2%

Earnings Yield (TTM)

INBX-9.9%

TSHA-10.4%

Dividend Yield (TTM)

INBXN/A

TSHAN/A

Rule of 40

INBX-100.0

TSHA-2,449.3

EV/GP/RG

INBXN/A

TSHAN/A

Ticker research

View INBX research View TSHA research

Metric	INBX Inhibrx Biosciences Inc	TSHA Taysha Gene Therapies Inc
Market & Valuation
Market Cap	$1.39B	$1.44B
Enterprise Value	$1.44B	$1.03B
Price	$95.01	$4.49
P/E Ratio	N/A	N/A
P/S Ratio	1,019.62x	261.77x
EV/Sales	1,050.29x	187.75x
EV/EBITDA	0.85x	0.00x
P/B Ratio	178.59x	3.90x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.89x	-7.77x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	664.56x
Revenue & Growth
Revenue (TTM)	$0	$5M
Revenue Growth (YoY)	-100.0%	-32.3%
Forward Rev Growth	282.8%	1272.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-2833.6%
Net Margin (TTM)	0.0%	-2728.0%
FCF Margin (TTM)	N/A	-2417.0%
Net Income (TTM)	$-138M	$-150M
FCF (TTM)	$-132M	$-133M
EPS (TTM)	-$8.82	-$0.41
ROE (TTM)	-26956.0%	-5619.0%
ROA (TTM)	-8348.0%	-4184.0%
ROIC (TTM)	-9241.0%	-4729.0%
Financial Health
Cash	$133M	$455M
Debt	$176M	$49M
Net Cash/Debt	$-43M	$406M
Current Ratio (TTM)	5.07x	17.76x
Quick Ratio (TTM)	4.76x	17.57x
Debt/Equity (TTM)	12.58x	0.13x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.17	1.37
52W Performance	182.7%	-11.3%
YTD Performance	26.6%	-14.5%
% from 52W High	-38.8%	-38.5%
% from 52W Low	237.4%	21.6%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.04x
FCF Yield (TTM)	-9.5%	-9.2%
Earnings Yield (TTM)	-9.9%	-10.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	-2,449.3
EV/GP/RG	N/A	N/A
Ticker research	View INBX research	View TSHA research

Valuation

P/S Ratio

TSHA

261.77x

INBX

1,019.62x

EV/FCF

INBX

-10.89x

TSHA

-7.77x

Growth & revenue

Revenue Growth TTM

TSHA

-32.3%

INBX

-100.0%

Forward Revenue Growth

TSHA

1272.3%

INBX

282.8%

Profitability & performance

Gross Margin

INBX

0.0%

TSHA

0.0%

ROE

TSHA

-5619.0%

INBX

-26956.0%

FCF Yield %

TSHA

-9.2%

INBX

-9.5%

52-Week Performance

INBX

182.7%

TSHA

-11.3%

Detailed metrics comparison

INBX

Inhibrx Biosciences Inc

TSHA

Taysha Gene Therapies Inc

Market Cap

INBX$1.39B

TSHA$1.44B

Enterprise Value

INBX$1.44B

TSHA$1.03B

Price

INBX$95.01

TSHA$4.49

P/E Ratio

INBXN/A

TSHAN/A

P/S Ratio

INBX1,019.62x

TSHA261.77x

EV/Sales

INBX1,050.29x

TSHA187.75x

EV/EBITDA

INBX0.85x

TSHA0.00x

P/B Ratio

INBX178.59x

TSHA3.90x

P/FCF Ratio

INBXN/A

TSHAN/A

EV/FCF

INBX-10.89x

TSHA-7.77x

PEG Ratio

INBXN/A

TSHAN/A

Forward P/E (NTM)

INBXN/A

TSHAN/A

Forward P/S (NTM)

INBXN/A

TSHA664.56x

Revenue (TTM)

INBX$0

TSHA$5M

Revenue Growth (YoY)

INBX-100.0%

TSHA-32.3%

Forward Rev Growth

INBX282.8%

TSHA1272.3%

Gross Margin (TTM)

INBX0.0%

TSHA0.0%

Operating Margin (TTM)

INBX0.0%

TSHA0.0%

EBITDA Margin (TTM)

INBX0.0%

TSHA-2833.6%

Net Margin (TTM)

INBX0.0%

TSHA-2728.0%

FCF Margin (TTM)

INBXN/A

TSHA-2417.0%

Net Income (TTM)

INBX$-138M

TSHA$-150M

FCF (TTM)

INBX$-132M

TSHA$-133M

EPS (TTM)

INBX-$8.82

TSHA-$0.41

ROE (TTM)

INBX-26956.0%

TSHA-5619.0%

ROA (TTM)

INBX-8348.0%

TSHA-4184.0%

ROIC (TTM)

INBX-9241.0%

TSHA-4729.0%

Cash

INBX$133M

TSHA$455M

Debt

INBX$176M

TSHA$49M

Net Cash/Debt

INBX$-43M

TSHA$406M

Current Ratio (TTM)

INBX5.07x

TSHA17.76x

Quick Ratio (TTM)

INBX4.76x

TSHA17.57x

Debt/Equity (TTM)

INBX12.58x

TSHA0.13x

Debt/Assets (TTM)

INBX0.0%

TSHA0.0%

Interest Coverage (TTM)

INBXN/A

TSHAN/A

Net Debt/EBITDA (TTM)

INBX0.00x

TSHA0.00x

Beta

INBX3.17

TSHA1.37

52W Performance

INBX182.7%

TSHA-11.3%

YTD Performance

INBX26.6%

TSHA-14.5%

% from 52W High

INBX-38.8%

TSHA-38.5%

% from 52W Low

INBX237.4%

TSHA21.6%

Asset Turnover (TTM)

INBX0.01x

TSHA0.04x

FCF Yield (TTM)

INBX-9.5%

TSHA-9.2%

Earnings Yield (TTM)

INBX-9.9%

TSHA-10.4%

Dividend Yield (TTM)

INBXN/A

TSHAN/A

Rule of 40

INBX-100.0

TSHA-2,449.3

EV/GP/RG

INBXN/A

TSHAN/A

Ticker research

View INBX research View TSHA research

Metric	INBX Inhibrx Biosciences Inc	TSHA Taysha Gene Therapies Inc
Market & Valuation
Market Cap	$1.39B	$1.44B
Enterprise Value	$1.44B	$1.03B
Price	$95.01	$4.49
P/E Ratio	N/A	N/A
P/S Ratio	1,019.62x	261.77x
EV/Sales	1,050.29x	187.75x
EV/EBITDA	0.85x	0.00x
P/B Ratio	178.59x	3.90x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.89x	-7.77x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	664.56x
Revenue & Growth
Revenue (TTM)	$0	$5M
Revenue Growth (YoY)	-100.0%	-32.3%
Forward Rev Growth	282.8%	1272.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-2833.6%
Net Margin (TTM)	0.0%	-2728.0%
FCF Margin (TTM)	N/A	-2417.0%
Net Income (TTM)	$-138M	$-150M
FCF (TTM)	$-132M	$-133M
EPS (TTM)	-$8.82	-$0.41
ROE (TTM)	-26956.0%	-5619.0%
ROA (TTM)	-8348.0%	-4184.0%
ROIC (TTM)	-9241.0%	-4729.0%
Financial Health
Cash	$133M	$455M
Debt	$176M	$49M
Net Cash/Debt	$-43M	$406M
Current Ratio (TTM)	5.07x	17.76x
Quick Ratio (TTM)	4.76x	17.57x
Debt/Equity (TTM)	12.58x	0.13x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.17	1.37
52W Performance	182.7%	-11.3%
YTD Performance	26.6%	-14.5%
% from 52W High	-38.8%	-38.5%
% from 52W Low	237.4%	21.6%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.04x
FCF Yield (TTM)	-9.5%	-9.2%
Earnings Yield (TTM)	-9.9%	-10.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	-2,449.3
EV/GP/RG	N/A	N/A
Ticker research	View INBX research	View TSHA research